Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 104,119,160
  • Shares Outstanding, K 1,639,930
  • Annual Sales, $ 19,427 M
  • Annual Income, $ 4,457 M
  • 36-Month Beta 1.18
  • Price/Sales 5.31
  • Price/Cash Flow 20.49
  • Price/Book 6.96

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.25 +12.87%
on 08/21/17
63.72 -0.36%
on 09/20/17
+7.07 (+12.53%)
since 08/18/17
3-Month
52.06 +21.96%
on 07/27/17
63.72 -0.36%
on 09/20/17
+7.83 (+14.07%)
since 06/20/17
52-Week
46.01 +37.99%
on 01/26/17
63.72 -0.36%
on 09/20/17
+7.93 (+14.27%)
since 09/20/16

Most Recent Stories

More News
New Global Report Finds Majority of People at High Risk of Stroke Not Being Screened for Common Risk Factors

New research released today by The Economist Intelligence Unit (EIU), a division of The Economist and a leader in global business intelligence, revealed that on average, more than 75 percent...

PFE : 35.99 (+1.52%)
BMY : 63.49 (+0.89%)
Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA

Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.

CELG : 144.24 (+0.54%)
MRK : 65.79 (-0.24%)
RHHBY : 31.9500 (+0.60%)
BMY : 63.49 (+0.89%)
Oncology Space in Focus this Week on ESMO Presentations

There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.

AZN : 32.93 (+0.80%)
MRK : 65.79 (-0.24%)
TEVA : 17.11 (-0.47%)
RHHBY : 31.9500 (+0.60%)
PFE : 35.99 (+1.52%)
BMY : 63.49 (+0.89%)
Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE

Bristol-Myers Squibb Company (BMY) enters into a collaboration and license agreement with Halozyme Therapeutics, Inc. (HALO).

MRK : 65.79 (-0.24%)
RHHBY : 31.9500 (+0.60%)
HALO : 16.68 (+1.58%)
BMY : 63.49 (+0.89%)
Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO

Key highlights this week include Teva's (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.

ACHN : 4.09 (+5.96%)
LLY : 82.02 (+0.35%)
AGN : 210.00 (-2.33%)
TEVA : 17.11 (-0.47%)
PFE : 35.99 (+1.52%)
GSK : 40.18 (+0.65%)
BMY : 63.49 (+0.89%)
Celebrities Brittany Daniel, Cynthia Hauser and Cole Hauser Show Their Support for Bristol-Myers Squibb Employees Riding Across the U.S. to Raise Money to Support Stand Up To Cancer

Actress, cancer survivor and Stand Up To Cancer (SU2C) Ambassador Brittany Daniel, her twin sister actress Cynthia Hauser, and Hauser's husband, actor Cole Hauser greeted a team of Bristol-Myers Squibb...

BMY : 63.49 (+0.89%)
Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology

--Halozyme to Receive $105 Million Upfront Payment, Plus Future Milestones and Royalties

HALO : 16.68 (+1.58%)
BMY : 63.49 (+0.89%)
Bristol-Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-nine cents ($0.39) per share on the $.10 par value Common Stock of the...

BMY : 63.49 (+0.89%)
Bristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors

Bristol-Myers Squibb Company (NYSE:BMY) today announced that its Board of Directors has elected Karen Vousden, Ph.D., to the Board, effective January 1, 2018. Dr. Vousden will serve...

BMY : 63.49 (+0.89%)
Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate

Nektar (NKTR) initiates phase I/II combo study on lead candidate NKTR-214 along with Tecentriq and Keytruda. The trial complements Nektar's ongoing PIVOT research clubbed with Opdivo.

MRK : 65.79 (-0.24%)
RHHBY : 31.9500 (+0.60%)
BMY : 63.49 (+0.89%)
NKTR : 21.39 (-1.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain;...

See More

Support & Resistance

2nd Resistance Point 64.31
1st Resistance Point 63.90
Last Price 63.49
1st Support Level 62.90
2nd Support Level 62.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.